These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35029320)

  • 1. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
    Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I
    CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
    Silvestro S; Valeri A; Mazzon E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
    Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
    Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.
    Kastanenka KV; Bussiere T; Shakerdge N; Qian F; Weinreb PH; Rhodes K; Bacskai BJ
    J Neurosci; 2016 Dec; 36(50):12549-12558. PubMed ID: 27810931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.
    Bastrup J; Hansen KH; Poulsen TBG; Kastaniegaard K; Asuni AA; Christensen S; Belling D; Helboe L; Stensballe A; Volbracht C
    J Alzheimers Dis; 2021; 79(1):249-265. PubMed ID: 33252074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive Immunotherapies Targeting Amyloid-
    Marković M; Milošević J; Wang W; Cao Y
    Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer's disease.
    Kandadi Muralidharan K; Tong X; Kowalski KG; Rajagovindan R; Lin L; Budd Haberlain S; Nestorov I
    CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):7-19. PubMed ID: 34697913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aducanumab in Alzheimer's Disease: A Critical Update.
    Ashique S; Sirohi E; Kumar S; Rihan M; Mishra N; Bhatt S; Gautam RK; Singh SK; Gupta G; Chellappan DK; Dua K
    Curr Med Chem; 2024; 31(31):5004-5026. PubMed ID: 37497712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
    Chen T; O'Gorman J; Castrillo-Viguera C; Rajagovindan R; Curiale GG; Tian Y; Patel D; von Rosenstiel P; von Hehn C; Salloway S; Hock C; Nitsch RM; Haeberlein SB; Sandrock A; Singhal P
    Alzheimers Dement; 2024 May; 20(5):3406-3415. PubMed ID: 38567735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease.
    Leinenga G; Koh WK; Götz J
    Alzheimers Res Ther; 2021 Apr; 13(1):76. PubMed ID: 33836798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
    Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
    J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer's disease.
    Lian Y; Jia YJ; Wong J; Zhou XF; Song W; Guo J; Masters CL; Wang YJ
    Mol Psychiatry; 2024 Feb; 29(2):297-305. PubMed ID: 38001337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aducanumab for the treatment of Alzheimer's disease: a systematic review.
    Rahman A; Hossen MA; Chowdhury MFI; Bari S; Tamanna N; Sultana SS; Haque SN; Al Masud A; Saif-Ur-Rahman KM
    Psychogeriatrics; 2023 May; 23(3):512-522. PubMed ID: 36775284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease.
    Madrasi K; Das R; Mohmmadabdul H; Lin L; Hyman BT; Lauffenburger DA; Albers MW; Rissman RA; Burke JM; Apgar JF; Wille L; Gruenbaum L; Hua F
    Alzheimers Dement; 2021 Sep; 17(9):1487-1498. PubMed ID: 33938131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ.
    Meilandt WJ; Maloney JA; Imperio J; Lalehzadeh G; Earr T; Crowell S; Bainbridge TW; Lu Y; Ernst JA; Fuji RN; Atwal JK
    Alzheimers Res Ther; 2019 Dec; 11(1):97. PubMed ID: 31787113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.
    Brody DL; Jiang H; Wildburger N; Esparza TJ
    Alzheimers Res Ther; 2017 Aug; 9(1):62. PubMed ID: 28818091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
    Lu D; Dou F; Gao J
    Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.